Artikel
Outcomes of previously-implanted SCS chronic pain patients converted to a new SCS system – European experience
Ergebnisse von zuvor implantierten SCS-Patienten mit chronischen Schmerzen, die auf ein neues SCS-System umgestellt wurden: In Europa gemachte Erfahrungen
Suche in Medline nach
Autoren
-
Philippe Rigoard
- University Hospital La Milétrie, Neurosurgery, Poitiers, Frankreich
-
Renaud Bougeard
- Clinique de la Sauvegarde, Neurosurgery, Lyon, Frankreich
-
Jose Emilio Llopis
- Hospital de la Ribera, Pain Management, Valencia, Spanien
-
Sylvie Raoul
- University Hospital Nantes, Neurosurgery, Nantes, Frankreich
-
Jan Vesper
- Universitätsklinikum Düsseldorf, Klinik für Neurochirurgie, Sektion Funktionelle Neurochirurgie und Stereotaxie, Düsseldorf, Deutschland
-
Hayat Belaid
- Fondation Adolphe de Rotschild, Neurosurgery, Paris, Frankreich
-
Yu Pei
- Boston Scientific Neuromodulation, Clinical Research, Valencia, CA, Vereinigte Staaten
-
Roshini Jain
- Boston Scientific Neuromodulation, Clinical Research, Valencia, CA, Vereinigte Staaten
-
Georgios Matis
- Universitätsklinikum Köln, Stereotaxy and Functional Neurosurgery, Köln, Deutschland
| Veröffentlicht: | 25. Mai 2022 |
|---|
Gliederung
Text
Background: Providing various waveforms and programming options can facilitate more customized delivery of analgesic neurostimulation to chronic pain patients implanted with a Spinal Cord Stimulation (SCS) device. However, technologies that offer such optimization capabilities are not accessible to long-term implanted patients using older devices, some of whom may experience loss or attenuation in therapeutic efficacy over time.
Objectives: Here, we assessed a cohort of previously-implanted patients who converted to a new SCS device capable of combination therapy (simultaneous or sequential delivery of multiple available waveforms), enhanced algorithmic-based stimulation field targeting, and waveform automation
Methods: This is a real-world, multicenter retrospective study of patients who were previously implanted with an SCS system (commercially-available device) who went on to convert to a new device (Boston Scientific) capable of multiple modality stimulation and/or combination therapy via an applicable device adaptor and new implantable pulse generator (IPG). Pain relief and other associated outcomes using both the previously-implanted SCS system and the newly connected device IPG are being collected
Results: Thirty-five patients have been assessed to date. Average age of those evaluated is 57-years with a mean baseline NRS score of 7.7±1.91 (prior to using new system) and were previously implanted for a duration of an average of 5.2±3.01 years. A 5.0-point improvement with the new system was observed versus a 1.5-point improvement using the previously-implanted system (note: previous devices consist of a range of different manufacturers). Sustained improvement with use of the new SCS system with multiple options was noted at mean last follow-up (1.0±0.96 years; NRS score Δ= 5.1; p<0.0001).
Conclusion: The initial findings of this European-based study so far support the postulate that previously-implanted SCS patients who are empowered to selectively use an assortment of different waveform programming options following IPG conversion can achieve sustained and robust pain relief.
